Cancer Type: Gynecologic

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201907060

A Phase I Study of PD-1 Inhibition with TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

202004237

De-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for Endometrial Cancer (DeCRESCEndo)

201704028

A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Cancer

201710005

NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer.

201806120

Ovation II: Protocol 201-17-201: A Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

201807008

A Phase IB Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, to Patients With Advanced Platinum-Sensitive Ovarian Cancer (YO40482)

201809090

AVB500-OC-002: A PHASE 1B/2 RANDOMIZED, CONTROLLED STUDY OF AVB-S6-500 IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN OR PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

201908011

GOG 3031: [TESARO 4010-03-001] A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY)

201909052

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC# 776864) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

201909083

A Phase I A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours